Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Buys Epidauros for $11.8M Cash to Upgrade PGx Play

NEW YORK (GenomeWeb News) — Clinical Data today said it has acquired privately held Epidauros Biotechnologie for €8.7 million ($11.8 million) in cash to help flesh out its pharmacogenomics abilities.
 
Clinical Data said it bought Epidauros for its portfolio of genetic biomarkers, expertise in genetic biomarker discovery, relationships with “leading” diagnostic companies, and its “fast-growing” pharmacogenomics services business.
 
Clinical Data CEO Drew Fromkin said the buy “will enhance Clinical Data's ability to bring valuable, proprietary pharmacogenetic tests to market.”
 
As part of the acquisition, Epidauros CEO Michael Lutz will join Clinical Data’s PGxHealth division as senior vice president of pharmacogenetic partnerships.
 
Epidauros’ intellectual property portfolio includes biomarkers in genes relating to “prominent” drug transporters such as MDR1(1), OCT1(2), MRP1(3), and cytochrome P450 drug metabolizing genes, such as CYP2B6(4) and CYP2D6(5).
 
MDR1 encodes P-glycoprotein, a key protein involved in drug transport that is known to modulate drug disposition, while CYP2B6, OCT1, and MRP1 are believed to help the body absorb, distribute, and metabolize “many drugs that span a variety of therapeutic classes and indications.”
 
According to Clinical Data, Epidauros will also provide the company with “additional scientific expertise, biotechnology partnering capabilities, and a deep understanding of European clinical markets.”

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.